Almanack Investment Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Almanack Investment Partners’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.3K	Buy	+10,705	New	+$35.6K	0.01%	317

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Almanack Investment Partners's RXRX Position: Q2 2026 in Review

Almanack Investment Partners opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 10,705 shares worth $39.3K. The stake represents 0.01% of the portfolio and ranks #317 among its holdings.

155 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Almanack Investment Partners held 10,705 shares of Recursion Pharmaceuticals worth $39.3K as of Q2 2026.
Recursion Pharmaceuticals was a new Almanack Investment Partners position in Q2 2026.
Recursion Pharmaceuticals made up 0.01% of Almanack Investment Partners's portfolio in Q2 2026, its #317 holding.
155 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Almanack Investment Partners's 13F filing for Q2 2026, filed 30 Jul 2026.